This clinical trial is focused on studying the effects of a treatment for patients with stage III epithelial ovarian cancer. The treatment involves a surgical procedure called primary cytoreductive surgery, which aims to remove as much of the cancer as possible. In some cases, this surgery is combined with a special type of chemotherapy known as hyperthermic intraperitoneal chemotherapy (HIPEC). This study aims to understand how adding HIPEC to the surgery might affect the overall survival of patients.

The trial involves several medications that are used during the treatment process. These include Paclitaxel Eugia, a solution for infusion that helps stop cancer cells from growing, and Sodium Thiosulfate, which is used to reduce side effects. Another medication used is Avastin, which works by preventing the growth of blood vessels that supply the tumor. Additionally, Cisplatin and Carboplatin are used, both of which are types of chemotherapy that help kill cancer cells. These medications are administered through an intravenous infusion, meaning they are given directly into a vein.

Participants in the study will undergo the primary cytoreductive surgery, and some will receive the additional HIPEC treatment. The study will monitor the patients over time to see how the treatments affect their survival and if the cancer returns. The goal is to determine if the combination of surgery and HIPEC provides a better outcome for patients with stage III epithelial ovarian cancer compared to surgery alone. The study will also look at the time it takes for patients to need further cancer treatment and any side effects experienced during the treatment period.